Stock listing

NASDAQ:TRAX First Tracks Biotherapeutics, Inc. Stock

Home listing (NASDAQ) of First Tracks Biotherapeutics, Inc.

Follow First Tracks Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TRAX

$41.64 USD -2.86 (-6.4%)

Close on Nov 20, 2026

Since Mar 10, 2026 +228.7% · daily closes, Mar 10, 2026 – Nov 20, 2026, adjusted for splits
Day range
$41.51 – $44.51 USDNov 20, 2026
Volume
504,364 sharesNov 20, 2026
Market cap
$1.75B USDAt the close on Nov 20, 2026 · price × 42.02M shares outstanding
Traded on an average day
$32.33M USDMedian day 617,731 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TRAX · Home$41.64 USD-2.86 (-6.4%)504,364$43.99$44.51$41.51$44.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TRAX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$41.64-2.86-6.4%$43.99$44.51$41.51504,364
$44.50+0.93+2.1%$43.17$45.44$43.17751,346
$43.57-2.99-6.4%$46.04$46.71$43.06586,451
$46.56-0.54-1.1%$46.52$48.48$46.29438,162
$47.10-1.60-3.3%$48.54$48.72$46.58462,165
$48.70-1.83-3.6%$48.94$50.15$46.97311,332
$50.53-1.80-3.4%$52.40$53.75$49.57487,936
$52.33+2.63+5.3%$49.11$54.78$48.641,150,314
$49.70+1.80+3.8%$48.90$50.41$47.58808,489
$47.90+2.47+5.4%$45.94$48.24$45.44587,920
$45.43-3.61-7.4%$49.10$49.10$44.47571,287
$49.04+2.70+5.8%$48.01$50.16$46.09881,330
$46.34+1.29+2.9%$45.54$46.71$45.54410,048
$45.05-0.03-0.1%$46.05$46.37$43.32426,382
$45.08-0.145-0.3%$45.03$45.87$43.36434,124
$45.23-0.495-1.1%$46.18$47.55$44.05471,526
$45.72+0.34+0.7%$44.84$46.37$44.79640,962
$45.38+1.90+4.4%$43.90$46.08$43.27617,731
$43.48-0.57-1.3%$43.10$45.42$41.83592,253
$44.05+0.91+2.1%$43.13$44.78$41.60849,800
$43.14+0.37+0.9%$42.27$44.14$41.67844,300
$42.77+1.52+3.7%$41.20$42.89$40.00711,500
$41.25+4.97+13.7%$36.67$41.78$36.281,033,400
$36.28+1.82+5.3%$35.01$37.26$35.001,434,200
$34.46-1.58-4.4%$37.07$37.24$33.381,041,400
$36.04+1.91+5.6%$34.69$36.30$33.991,578,500
$34.13+2.45+7.7%$31.28$34.32$30.88982,100
$31.68-2.37-7.0%$33.72$34.36$31.121,112,300
$34.05+2.20+6.9%$39.45$40.50$33.027,310,200
$31.85-0.16-0.5%$31.96$33.28$30.71855,200
$32.01+1.42+4.6%$33.31$33.31$30.111,483,400
$30.59-0.80-2.5%$30.91$31.75$30.53355,500
$31.39-1.60-4.8%$33.02$33.02$30.96613,800
$32.99-0.29-0.9%$34.44$34.44$30.88667,800
$33.28-0.64-1.9%$34.45$35.41$32.501,167,900
$33.92-1.52-4.3%$35.20$36.03$33.77564,100
$35.44-0.54-1.5%$36.74$37.31$35.32610,600
$35.98-0.67-1.8%$36.61$36.80$34.99645,500
$36.65+2.23+6.5%$34.40$37.24$33.55674,500
$34.42-1.41-3.9%$35.82$35.82$33.66356,500
$35.83-0.83-2.3%$36.11$37.09$34.571,144,100
$36.66-4.37-10.7%$41.14$41.38$36.57658,400
$41.03+2.04+5.2%$39.43$42.24$39.37893,200
$38.99+0.39+1.0%$38.87$39.92$38.04661,300
$38.60-0.60-1.5%$40.20$41.48$38.452,590,700
$39.20+0.20+0.5%$39.91$41.90$39.13554,800
$39.00+0.53+1.4%$40.25$40.89$38.57637,200
$38.47+0.90+2.4%$37.22$39.02$35.98526,000
$37.57+1.13+3.1%$36.17$38.50$36.17442,600
$36.44-1.54-4.1%$38.08$38.30$35.49619,900
$37.98-1.59-4.0%$39.35$40.69$37.40389,100
$39.57-2.23-5.3%$40.74$42.79$39.31478,600
$41.80+1.34+3.3%$39.45$43.78$39.20540,700
$40.46-2.05-4.8%$41.06$42.00$40.38456,200
$42.51-2.77-6.1%$44.57$45.56$42.29717,000
$45.28+4.11+10.0%$44.48$47.98$44.261,365,300
$41.17-0.67-1.6%$41.57$42.62$40.75557,500
$41.84-0.020.0%$41.67$42.44$39.83687,000
$41.86-2.88-6.4%$44.36$44.74$41.69410,000
$44.74+0.55+1.2%$44.09$45.39$43.80375,300
$44.19-0.92-2.0%$45.84$45.84$43.73561,700
$45.11+1.83+4.2%$43.27$46.48$43.27441,929
$43.28+0.17+0.4%$43.47$44.64$42.56677,251
$43.11+1.21+2.9%$42.98$44.79$40.72528,000
$41.90-3.60-7.9%$45.50$45.99$41.78478,200
Ticker
NASDAQ:TRAX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All First Tracks Biotherapeutics, Inc. news

First Tracks Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
10 in the last 12 months · 10 in all · newest Nov 3, 2026 · oldest 2026
Decks
1 deck · latest Oct 13, 2026

Where First Tracks Biotherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TRAX · Home listing · This pageNASDAQUnited StatesUSD
BMV:TRAXBMVMexicoMXN
BOATS:TRAXBOATSUnited StatesUSD
BIVA:TRAXBIVAMexicoMXN
Dusseldorf:B43DusseldorfGermanyUSD
Hamburg:B43HamburgGermanyEUR

Valuation

Price/book 11.6× against a median of 5.0×: the highest of 10 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.60B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
11.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.80

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
First Tracks Biotherapeutics, Inc. · NASDAQ:TRAXUS$1.75BUS$1.60Bn/an/an/a11.6×n/a0.0×1.80
Zymeworks Inc. · NASDAQ:ZYMEUS$1.84BUS$2.08B42.5×7.8×40.6×7.1×16.3%1.3×0.69
Vera Therapeutics, Inc. · NASDAQ:VERAUS$1.84BUS$1.53Bn/a149×n/a5.5×n/a0.2×1.13
Hemab Therapeutics Holdings, Inc. · NASDAQ:COAGUS$1.84BUS$1.41Bn/an/an/a4.3×n/a0.0×0.61
Braveheart Bio, Inc. · NASDAQ:BRVEUS$1.84BUS$1.71Bn/an/an/a3.7×n/a0.0×n/a
Septerna, Inc. · NASDAQ:SEPNUS$1.84BUS$1.38Bn/a14.3×n/a4.3×−61.3%0.1×0.95
Replimune Group, Inc. · NASDAQ:REPLUS$1.81BUS$1.60Bn/an/an/a8.8×n/a0.5×0.78
Neuren Pharmaceuticals Limited · ASX:NEUUS$1.76BUS$1.57B87.3×36.7×108×8.0×47.1%0.0×n/a
Stoke Therapeutics, Inc. · NASDAQ:STOKUS$1.75BUS$1.43Bn/a50.8×n/a5.0×−862.1%0.0×0.78
Maze Therapeutics, Inc. · NASDAQ:MAZEUS$1.74BUS$1.39Bn/a69.6×n/a4.1×−757.4%0.1×0.66
Lycia Therapeutics, Inc. · NASDAQ:LYCAUS$1.72BUS$1.60Bn/a237×n/an/a−540.9%n/an/a
Median of the othersUS$1.82BUS$1.55B64.9×50.8×74.1×5.0×−301.1%0.1×0.78

Forecasts

9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
75.17 USD · Analysts' mean
EPS, year to Dec 2026
-3.87 · 10 analysts

Team and board

OfficerRole
Nick MontemaranoVice President, Investor Relations

Events

QuarterResultsShare move
Q3 2026Nov 3, 2026 · After close+5.8%
Q2 2026Aug 12, 2026 · After close−4.5%
Q1 2026May 15, 2026−2.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck51 slidesOct 13, 2026

Open Decks

Financings

RaiseDate
Private placement of shares of common stock
Closed: US$200M raised · US$32.75 a share · Leerink Partners +3
Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities
Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital
Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist
Nov 3, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue00
Cost of revenue139.6M152.3M
Gross profit-139.6M-152.3M
Research and development139.6M152.3M97.6M
Selling, general and administrative39.4M28.8M20.9M
Operating income-179.0M-181.1M-118.5M
Depreciation and amortization2.42M2.40M2.38M
EBITDA-176.6M-178.7M-116.1M
Income before tax-166.1M-163.7M-106.2M
Net income-166.1M-163.7M-106.2M
Earnings per share, basic-4.78-4.71-3.05

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents238.2M123.1M36.0M
Short-term investments73.4M262.3M354.9M
Current assets316.4M389.9M398.6M
Total assets330.5M441.9M444.1M
Accounts payable3.11M3.79M2.42M
Current liabilities31.0M36.2M18.2M
Total debt14.1M16.0M17.8M
Total liabilities43.1M50.3M34.3M
Shareholders' equity287.5M391.6M409.8M
Shares outstanding34.7M34.7M34.7M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-142.9M-125.8M-93.0M
Capital spending-87.0K-358.0K-807.0K
Free cash flow-143.0M-126.2M-93.8M
Cash from investing228.0M95.4M144.8M
Cash from financing30.0M117.5M-87.1M
Change in cash115.1M87.1M-35.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
424B3 · ProspectusNov 4, 2026Offer documentSEC
424B3 · ProspectusNov 4, 2026Offer documentSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
All 100 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveOct 30, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
S-1 · Registration statementOct 26, 2026Offer documentSEC
8-K · Current reportOct 20, 2026Material contractSEC
8-K · Current reportOct 15, 2026Material contractSEC
8-K · Current reportOct 13, 2026Current reportSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
424B3 · ProspectusAug 13, 2026Offer documentSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
3/A · Initial statement of ownership, amendedAug 7, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 7, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 7, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
8-K · Current reportJun 22, 2026Material contractSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 12, 2026Insider tradeSEC
424B3 · ProspectusMay 15, 2026Offer documentSEC
424B3 · ProspectusMay 14, 2026Offer documentSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 13, 2026Other filingsSEC
CORRESP · Letter to the SECMay 8, 2026Other filingsSEC
S-1 · Registration statementMay 8, 2026Offer documentSEC
UPLOAD · Letter from the SECMay 6, 2026Other filingsSEC
DRS · Draft registration statementMay 1, 2026Offer documentSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 23, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 22, 2026Big-stake noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 22, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
8-K · Current reportApr 20, 2026Acquisition or disposalSEC
S-8 · Registration statement for employee plansApr 17, 2026Offer documentSEC
8-K · Current reportApr 2, 2026Current reportSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
SEC STAFF ACTIONApr 1, 2026Other filingsSEC
CERT · Exchange's certificate of listingApr 1, 2026Other filingsSEC
10-12B/AMar 27, 2026Other filingsSEC
10-12BMar 3, 2026Other filingsSEC
DRS · Draft registration statementFeb 6, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from First Tracks Biotherapeutics, Inc.’s releases · as of Nov 3, 2026

Common shares
42,017,901
Fully diluted
42,017,901

Fully diluted

LineSharesAs of
Common shares42,017,901Oct 29, 2026

Share count over time

CountShares
Oct 29, 202642,017,901

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
EcoR1 Capital, LLC3.17M7.6%US$113MSep 30, 2026
TCG Crossover Management, LLC2.9M6.9%US$103MSep 30, 2026
BlackRock2.6M6.2%US$92MSep 30, 2026
Affinity Asset Advisors, LLC2.08M5.0%US$73.7MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.08M4.9%US$73.6MSep 30, 2026
Vanguard2.05M4.9%US$72.6MSep 30, 2026
Fidelity1.75M4.2%US$61.9MSep 30, 2026
State Street1.61M3.8%US$57.1MSep 30, 2026
Janus Henderson1.1M2.6%US$38.8MSep 30, 2026
Bank of America1.01M2.4%US$35.8MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Woodline Partners LP918K2.2%US$32.5MSep 30, 2026
Geode Capital837K2.0%US$29.7MSep 30, 2026
Sanofi822K2.0%US$29.1MSep 30, 2026
Trails Edge Capital Partners, LP814K1.9%US$28.8MSep 30, 2026
Invesco781K1.9%US$27.7MSep 30, 2026
Morgan Stanley756K1.8%US$26.8MSep 30, 2026
Palo Alto Investors LP741K1.8%US$26.3MSep 30, 2026
Stempoint Capital LP650K1.5%US$23MSep 30, 2026
Citadel624K1.5%US$22.1MSep 30, 2026
683 Capital Management, LLC600K1.4%US$21.3MSep 30, 2026
Goldman Sachs503K1.2%US$17.8MSep 30, 2026
Jennison Associates LLC499K1.2%US$17.7MSep 30, 2026
Baker Bros. Advisors LP473K1.1%US$16.8MSep 30, 2026
Point72 Asset Management, L.P.418K0.99%US$14.8MSep 30, 2026
Sofinnova Investments, Inc.384K0.91%US$13.6MSep 30, 2026
Federated Hermes, Inc.290K0.69%US$10.3MSep 30, 2026
Schwab277K0.66%US$9.83MSep 30, 2026
Northern Trust275K0.65%US$9.75MSep 30, 2026
Mpm Bioimpact LLC254K0.61%US$9.02MSep 30, 2026
Millennium247K0.59%US$8.75MSep 30, 2026
Boxer Capital Management, LLC240K0.57%US$8.51MSep 30, 2026
Kennedy Capital Management LLC227K0.54%US$8.04MSep 30, 2026
Lord, Abbett & Co. LLC218K0.52%US$7.71MSep 30, 2026
Ameriprise172K0.41%US$6.08MSep 30, 2026
Vestal Point Capital, LP170K0.40%US$6.02MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.163K0.39%US$5.77MSep 30, 2026
Sphera Funds Management LTD.160K0.38%US$5.68MSep 30, 2026
DWS159K0.38%US$5.65MSep 30, 2026
Soleus Capital Management, L.P.141K0.33%US$4.98MSep 30, 2026
BNP Paribas122K0.29%US$4.32MSep 30, 2026
Rockefeller Capital Management L.P.115K0.27%US$4.09MSep 30, 2026
SummitTX Capital, L.P.103K0.24%US$3.64MSep 30, 2026
Fred Alger Management, LLC98,4060.23%US$3.49MSep 30, 2026
Ensign Peak Advisors, Inc96,9360.23%US$3.44MSep 30, 2026
Granahan Investment Management, LLC94,7210.23%US$3.36MSep 30, 2026
Nomura93,7320.22%US$3.32MSep 30, 2026
UBS89,8330.21%US$3.18MSep 30, 2026
Verition Fund Management LLC89,3600.21%US$3.17MSep 30, 2026
J. Goldman & Co LP87,0140.21%US$3.08MSep 30, 2026
BNY86,9910.21%US$3.08MSep 30, 2026

This page holds 50 of 175 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.11M2.6%US$22.4MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF930K2.2%US$18.7MJun 30, 2026
iShares Russell 2000 ETF608K1.4%US$12.2MJun 30, 2026
Select Health Care Portfolio400K0.95%US$6.38MMay 31, 2026
Fidelity Advisor Biotechnology Fund341K0.81%US$15MJul 31, 2026
Vanguard Extended Market Index Fund309K0.74%US$6.22MJun 30, 2026
Federated Hermes Kaufmann Small Cap Fund290K0.69%US$12.8MJul 31, 2026
Fidelity Small Cap Index Fund255K0.61%US$11.2MJul 31, 2026
Fidelity Advisor Health Care Fund200K0.48%US$8.81MJul 31, 2026
Victory Science & Technology Fund188K0.45%US$8.27MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Strategic Equity Fund153K0.36%US$3.08MJun 30, 2026
Fidelity Series Small Cap Core Fund153K0.36%US$6.73MJul 31, 2026
iShares Russell 2000 Growth ETF151K0.36%US$3.03MJun 30, 2026
Fidelity Extended Market Index Fund102K0.24%US$1.62MMay 31, 2026
Vanguard Explorer Fund98,2620.23%US$4.33MJul 31, 2026
Schwab U.S. Small-Cap ETF94,5490.23%US$1.51MMay 31, 2026
Nomura Healthcare Fund93,7320.22%US$1.89MJun 30, 2026
Vanguard Russell 2000 Index Fund93,6290.22%US$1.49MMay 31, 2026
VIP Health Care Portfolio80,0000.19%US$1.61MJun 30, 2026
iShares Micro-Cap ETF78,4870.19%US$1.58MJun 30, 2026
iShares Russell 2000 Value ETF65,2290.16%US$1.31MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund62,3000.15%US$994KMay 31, 2026
Tema Oncology ETF58,4190.14%US$932KMay 31, 2026
Schwab Small-Cap Index Fund56,7740.14%US$2.5MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund48,1900.11%US$970KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF45,4850.11%US$915KJun 30, 2026
Fidelity Small-Mid Multifactor ETF45,0900.11%US$1.99MJul 31, 2026
Master Small Cap Index Series43,6290.10%US$878KJun 30, 2026
Vanguard Health Care Index Fund41,8140.10%US$667KMay 31, 2026
Fidelity Total Market Index Fund37,0640.09%US$592KMay 31, 2026
Alger Small Cap Growth Fund32,9150.08%US$1.45MJul 31, 2026
Victory Small Cap Stock Fund31,9950.08%US$1.41MJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares31,6150.08%US$1.39MJul 31, 2026
Nuveen Small Cap Blend Index Fund31,0510.07%US$1.37MJul 31, 2026
Fidelity Series Total Market Index Fund29,8860.07%US$477KMay 31, 2026
Schwab Small-Cap Equity Fund28,4850.07%US$1.25MJul 31, 2026
EQ/2000 Managed Volatility Portfolio25,4180.06%US$511KJun 30, 2026
Schwab Total Stock Market Index Fund25,2910.06%US$1.11MJul 31, 2026
Select Biotechnology Portfolio23,3000.06%US$372KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF20,6550.05%US$910KJul 31, 2026
EQ/Small Company Index Portfolio20,2900.05%US$408KJun 30, 2026
Dimensional U.S. Small Cap ETF18,8790.04%US$831KJul 31, 2026
Virtus Biotech Clinical Trials Etf17,6200.04%US$776KJul 31, 2026
Fidelity Nasdaq Composite Index Fund17,1750.04%US$274KMay 31, 2026
LVIP State Street Small-Cap Index Fund17,0000.04%US$342KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund16,9380.04%US$270KMay 31, 2026
Avantis U.S. Equity ETF16,5640.04%US$264KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund16,2360.04%US$327KJun 30, 2026
Nuveen Equity Index Fund15,5960.04%US$687KJul 31, 2026
Fidelity Small Cap Growth Index Fund15,2540.04%US$307KJun 30, 2026

This page holds 50 of 171 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ware J. Anthony
Director
Sale39,265USD 44.78US$1.76MSep 2, 2026
EcoR1 Capital, LLC
10% owner
Sale4,705,575USD 13.81US$65MApr 20, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%6.3MOct 30, 2026Schedule 13G
EcoR1 Capital, LLC9.10%3.17MApr 20, 2026Schedule 13G
Chen Yu8.30%2.9MJun 30, 2026Schedule 13G
BlackRock, Inc.7.20%2.56MSep 30, 2026Schedule 13G
Sirenia Capital Management LP7.20%2.5MJun 30, 2026Schedule 13G
Adage Capital Management, L.P.5.81%2.08MSep 30, 2026Schedule 13G
Affinity Asset Advisors, LLC5.80%2.03MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Schmid
Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past)
Director · Since at least Apr 1, 2026
John Orwin
Other companies: CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); AnaptysBio, Inc. (Board Chairman of First Tracks Bio Former CEO of Relypsa · Since at least Sep 15, 2023); Travere Therapeutics, Inc. (Director · Since at least Mar 23, 2017); Atreca Inc (PRESIDENT & CEO, Director · Jun 19, 2019 – Apr 11, 2024 · Past); Seagen Inc (Director · Jan 10, 2014 – Dec 14, 2023 · Past); Relypsa Inc (President & CEO, Director · Nov 14, 2013 – Sep 1, 2016 · Past); Affymax Inc (Director · Apr 12, 2010 – Jun 27, 2013 · Past); NeurogesX Inc (Director · Nov 19, 2009 – Jun 7, 2012 · Past)
Director · Since at least Apr 1, 2026
Dennis M Fenton
Other companies: AnaptysBio, Inc. (Director · Since at least Mar 5, 2018); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past); Pfenex Inc (Director · May 6, 2016 – May 5, 2017 · Past)
Director · Since at least Apr 1, 2026
Rita Jain
Other companies: SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024); AnaptysBio, Inc. (Director · Since at least Jan 3, 2024)
Director · Since at least Apr 1, 2026
J Anthony Ware
Other companies: AnaptysBio, Inc. (Director · Since at least Aug 22, 2017)
Director · Since at least Apr 1, 2026
Magda Marquet
Other companies: Immix Biopharma, Inc. (Director · Since at least May 22, 2026)
Director · Since at least Jun 15, 2026
Nick Montemarano
Other companies: AnaptysBio, Inc. (Executive Director, Investor Relations · Since at least Mar 3, 2026)
Vice President, Investor Relations · Since at least Nov 3, 2026
Benjamin StoneChief Business Officer · Since at least Apr 20, 2026

Open People

Log in to ask 6ix AI your own questions about First Tracks Biotherapeutics, Inc.